Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome
Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome
复制标题
DOI：
10.1007/s10620-007-9919-9
复制
发表时间：
2008-03-01
影响因子：
3.1
通讯作者：
Castellino, Pietro
中科院分区：
文献类型：
--
作者：
Neri, Sergio;Pulvirenti, Davide;Castellino, Pietro
目的：肝肾综合征(HRS)是一种肾前性功能障碍，通常发病于以腹水为主诉的肝硬变患者。我们研究了肝肾综合征患者应用特利加压素后肾功能的改善情况和治疗后的生存时间。52例确诊为肝肾综合征的肝硬变患者接受特利加压素联合白蛋白治疗(A组)和单纯白蛋白治疗(B组)。监测肝肾功能、血浆肾素活性和血浆醛固酮水平。结果：A组患者与B组比较，肾功能有明显改善(p<；0.001)，生存概率较高(p<；0.0001)。结论：我们的结果似乎证实了特利加压素联合白蛋白的应用改善了肝硬变和I型HRS患者的肾功能，而且肝肾综合征的逆转与提高存活率密切相关。
Purpose: Hepatorenal syndrome (HRS) is a pre-renal-like dysfunction that generally onsets in cirrhotic patients presenting ascites. We investigated the improvement of renal function in subjects with hepatorenal syndrome after terlipressin administration and the survival times after this treatment. Fifty-two patients affected by cirrhosis, with diagnosis of hepatorenal syndrome were treated with intravenous terlipressin plus albumin (group A) or with albumin alone (group B). Liver and renal function, plasma renin activity, and aldosterone plasma levels were monitored. Results: Patients from group A showed a significant improvement (p < 0.001) of renal function valued by creatinine rate compared with the results obtained in group B. The probability of survival was higher in the group A (p < 0.0001). Conclusions: Our results seem to confirm that the administration of terlipressin plus albumin improves renal function in patients with cirrhosis and type I HRS and that a reversal of hepatorenal syndrome is strongly associated with improved survival.